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The outbreak of Coronavirus Disease 2019 (COVID-19) caused by the
novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has led to a global health emergency.1 Compared to the general popu-
lation, patients with hemoglobin disorders such as sickle cell disease
(SCD) or thalassemia are expected to be more severely affected by
COVID-19 due to their preexisting chronic morbidities.2 The Centers
for Disease Control and Prevention does not report any specific indi-
cations for patients with hemoglobinopathies. However, it can be
hypothesized that the rapid spread of the virus may render these
patients fragile when fighting the infection.
SCD, a hematological condition with functional asplenia, puts
patients at a greater risk to develop acute pulmonary complications,
including viral infections.2 A study by Hussain et al reported four SCD
cases that tested positive for COVID-19.3 These cases initially pres-
ented to the emergency department for a typical vaso-occlusive crisis
(VOC), and the clinical course of their SARS-CoV-2 infection was
rather mild. Patients had a history of respiratory complications, such
as acute chest syndrome (ACS), asthma, or pulmonary embolism,
which may be potential risk factors for progressive COVID-19 pulmo-
nary disease in patients with SCD.3 A series of isolated cases of ACS
in SCD patients positive for COVID-19 has been recently reported.4,5
Therefore, very little clinical experience of infected patients with SCD
currently exists. For this reason, we believe that certain recommenda-
tions must be followed by healthcare professionals treating any SCD
patient infected with SARS-CoV-2.
First, it is important to recognize the clinical manifestations sug-
gestive of rapidly progressive ACS, including multi-organ failure,
hepatic dysfunction, thrombocytopenia, and acute kidney injury.
Healthcare professionals should differentiate between pneumonia or
ACS, and the more diffuse ground glass appearance that is commonly
associated with SARS-CoV-2 infection. Caution should be taken
towards increased pulmonary pressures and right heart failure as
symptoms suggestive of pulmonary hypertension, which can increase
the risk of complications of a SARS-CoV-2 infection. Pulmonary and
cardiac specialists should be consulted in case of suspicion of pulmo-
nary hypertension. It is also important to recognize the high risk of life-
threatening sepsis among SCD patients, whose functional hypo-
splenism renders them vulnerable to superimposed bacterial infections.
In terms of the therapeutic options for these patients, we recom-
mend early aggressive simple or exchange blood transfusions for SCD
patients diagnosed with COVID-19 and manifesting fever and cough,
have worsening anemia, evidence of hypoxia and/or lung imaging
changes. Exchange transfusions should be initiated in case of
progressively worsening hypoxemia and clinical deterioration. Blood
products shortage is anticipated during the pandemic, so pre-
established transfusion thresholds should be adjusted to include
mainly patients with severe anemia or with complications, namely
ACS or stroke. There currently exists no evidence that being on
hydroxyurea would increase SARS-CoV-2 infection risk. However, it is
advisable to avoid the routine use or increasing doses of hydroxyurea
to reduce the need for repeated phlebotomy and hospital visits.2,6 In
areas where severe blood shortages are expected due to the pan-
demic, a low dose of hydroxyurea is recommended in all pediatric
patients with sickle cell anemia, who receive regular blood transfusion
therapy for primary or secondary stroke prevention.7 In the absence
of regular blood transfusion therapy, hydroxyurea treatment will also
decrease the incidence rates of acute vaso-occlusive pain and ACS
events.7 Noteworthy, a treatment with one single dose of tocilizumab
(8 mg/kg) was successfully used to treat an adult SCD patient with
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pneumonia; it was related to COVID-19 infection associated
with ACS.8
Respiratory measures for these patients should not include
aerosol-based interventions, but rather nebulizers and metered-dose
inhalers, if the room is non-negative pressure. A negative pressure
room for non-invasive ventilation, high flow oxygen, and bronchos-
copy should also be used.9 Patients with SCD are often prescribed
non-steroidal anti-inflammatory drugs, angiotensin converting enzyme
inhibitors, and angiotensin II receptor blockers. There is emerging data
regarding the possible negative effects of these classes of drugs on
SCD patients being treated for COVID-19.9 As data is emerging on a
day-by-day basis, clinicians should search for the latest evidence in
that regard when encountering patients on these medications.
There is emerging evidence from case series and retrospective
studies that severe SARS-CoV-2 infection can be complicated by an
increased risk of coagulopathy. In addition, SCD patients often experi-
ence an increased frequency of viscosity-related events, and have an
increased risk for venous thromboembolic events. This suggests that
they may even be at higher risk compared to COVID-19 patients who
do not have SCD. Although data suggests that pediatric COVID-19
patients have a milder clinical course compared to adults, thrombosis
has been reported. All adult or pediatric SCD patients with severe
COVID-19 should therefore be given prophylactic doses of anticoagu-
lant, unless there is an indication for full anticoagulation.10 Recent data
suggests a reduced 28-day mortality in severely ill COVID-19 patients
who received low-molecular-weight heparin or unfractionated heparin.
Moreover, therapeutic anticoagulation strategies in these patients
should also be taken into consideration. The active application of
anticoagulants, such as heparin, has been recommended but still needs
validation by evidence. There is a close association between elevated
D-dimer levels and pro-inflammatory cytokines with disease severity in
patients with COVID-19.11 Blood tests on admission should include
platelet count, fibrinogen, and D-dimer levels. It is also recommended
to check D-dimer levels every 24-48 hours during hospitalization. Stem
cell transplants and gene therapy approaches should be deferred for
these patients until the pandemic resolves. If the patient is on one of
the recently approved drugs for SCD such voxelotor or crizanlizumab, it
is advised that they continue therapy. If not yet started, delaying the
new drug initiation should be considered.10
While thalassemia patients do not have the same risk for pul-
monary infections as patients with SCD, they also have underly-
ing comorbidities (stemming from ineffective erythropoiesis,
chronic hemolytic anemia and primary or secondary iron overload)
that may also make them vulnerable to complications of the
SARS-CoV-2 infection.2 A study by Motta et al provided prelimi-
nary data from an Italian experience, showing that patients with
thalassemia have mild clinical presentation of SARS-CoV-2 infec-
tion.12 They included 10 cases of transfusion-dependent thalas-
semia (TDT) and one case of non-transfusion-dependent
thalassemia (NTDT), all of whom had thalassemia-related com-
orbidities and were diagnosed with COVID-19. Six patients
required hospitalization and none died. Except for one patient
with myelosuppression, there was no increase in blood
requirements.12 A larger sample is required to better understand
the impact of COVID-19 in thalassemia patients, but these data
suggest that it may not be more severe than the general popula-
tion. While there is very little clinical experience of infected
patients with thalassemia, we believe that certain recommenda-
tions must be followed by healthcare professionals treating any
thalassemia patient with COVID-19.
Clinicians dealing with COVID-19 thalassemia patients should
take into consideration the possibility of adrenal insufficiency, particu-
larly in patients with hemodynamic instability. The need for low dose
glucocorticoid supplementation should be considered, while keeping
in mind that corticosteroids slow down clearance of viral RNA from
respiratory tract in SARS-CoV-2 infection, and increase the complica-
tion rate. Both, intravascular and extravascular hemolysis, can occur in
thalassemia patients. Clinicians should therefore closely monitor blood
counts of thalassemia patients with COVID-19, and caution should be
maintained towards the possibility of exacerbated hemolytic anemia
in the setting of acute viral infection. As for those patients with car-
diac disease, routine monitoring for iron overload and related cardio-
myopathy should be continued. Although thalassemia is known to be
associated with a hypercoagulable state, there is currently no data on
increased risk of thromboembolic events among thalassemia patients
with COVID-19. However, since there is emerging evidence that
severe SARS-CoV-2 infection has an increased risk of coagulopathy,
we recommend giving prophylactic anticoagulation to all patients with
severe COVID-19.
Patients with thalassemia, particularly those in the older age
group, are most likely to have been splenectomized. If these patients
are infected with SARS-CoV-2, the risk of developing a superimposed
secondary bacterial infection, and triggering a life-threatening sep-
sis should be considered. Therefore, thorough evaluation of any
splenectomized thalassemia patient presenting with fever should
be made and antibiotics should be initiated for possible bacterial
infection. As for blood transfusions, the patientʼs chronic transfu-
sion regimen must be maintained, as there is no evidence to date
that COVID-19 may be transmitted through blood. If thalassemia
patients are exposed to SARS-CoV-2 but are asymptomatic, iron
chelation therapy should not be stopped. However, should the
patient become symptomatic, it is advisable to interrupt iron chela-
tion therapy.6,13 Unless conditioning has already been initiated,
stem-cell transplants and gene therapy should be deferred for
these patients until the pandemic resolves.13 Should a patient be
on the novel erythropoiesis maturation agent luspatercept, therapy
should be maintained even if the patient is diagnosed with COVID-
19, as there is no evidence that it should be discontinued in this
case scenario. If not yet started, delaying the new drug initiation
should be considered.13
The consequences of COVID-19 in patients with SCD and thalas-
semia are not yet well delineated. Comprehensive and detailed
reporting by international medical experts, policy makers, govern-
ments, and non-governmental organizations of the clinical course and
outcomes in this patient population is needed. This will enhance the
understanding of the infection in this patient group and will lead to
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more evidence-based management recommendations for these
patients. Until more data arise, the recommendations we provide
herein can be used based on cliniciansʼ best judgment.
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Granulocyte-colony
stimulating factor in COVID-
19: Is it stimulating more than
just the bone marrow?
To the Editor:
Granulocyte-colony stimulating factor (GCSF) is routinely adminis-
tered in cancer patients as prophylaxis or treatment of neutropenia.
Although the safety profile of GCSF use in patients with symptomatic
COVID-19 disease is unclear, lung findings from autopsies of patients
showed neutrophil extravasation in the alveolar space.1 It is known
that severe cases of COVID-19 have been reported to have a higher
absolute neutrophil count (ANC)-absolute lymphocyte count (ALC)
ratio2; both reported findings raise questions about the appropriate
timing of administering growth factors to neutropenic patients with
SARS-CoV-2 infection.
Although clear causal evidence of GCSF administration leading
to worse outcomes in COVID-19 patients does not yet exist, there
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